Rhapsody Venture Partners Research
Investment Thesis
Rhapsody Venture Partners is a Cambridge, Massachusetts-based venture capital firm specializing exclusively in hard-science and industrial deep tech. Founded in 2016 (some databases list 2012), the firm positions itself as "the innovator's partner" and describes its work as being "specialist investors and co-creators of startups in the hard sciences." Their stated philosophy is a direct counterpoint to consumer software investing: "Software is eating the world, but we're eating hard tech." Rhapsody believes the next several decades will be shaped by critical progress in hard technology, driven by population growth and resource constraints, and that hard-tech investing requires specialized, time-consuming, and expensive diligence that generalist VCs are structurally mismatched to provide.
The firm explicitly targets innovations emerging from academic research — university scientists, graduate students, and post-docs translating years of lab work into commercial ventures. Rhapsody frequently partners with university technology-transfer offices and industrial innovation partners, functioning as an ecosystem builder rather than a purely transactional investor.
Stage Focus
Rhapsody is a seed-stage lead investor. Typical first checks fall in the $500K–$2MM range, and the firm frequently participates in follow-on syndicates (Series A and beyond) for existing portfolio companies as they scale.
Check Size
- First check: $500K–$2MM (seed stage)
- Follow-on participation in Series A/B rounds for portfolio companies (e.g., NODAR's $12MM Series A, ph7's $25.6MM Series B)
Lead Tendency
Rhapsody positions itself as a lead investor at seed ("Rhapsody leads seed round in Polaris," "Rhapsody Leads $7MM Series A In Holiferm," multiple press releases titled "[Company] Secures $X Investment from Rhapsody"). The firm also participates alongside other leads in later rounds (e.g., IQ Capital led Nuclear Turbines' £15M round with Rhapsody as a participant).
Recent Activity
Rhapsody has been actively deploying through 2025 and 2026:
- July 2026: Participated in Nuclear Turbines' £15M round (led by IQ Capital, with Zero Carbon Capital and Empirical Ventures)
- December 2025: Portfolio company ph7 raised a $25.6M Series B led by Fine Structure to scale critical-metals extraction technology
- October 2025: SpinDrive (magnetic bearing systems) raised growth funding
- May 2024: Led/participated in Wavelogix's $3M investment
- January 2024: Led Cnergreen's $2M investment
- December 2023: Led Polaris EO's (Polaris Electro-Optics) seed round for integrated photonics
- April 2022: Participated in NODAR's $12MM Series A alongside NEA
Portfolio Highlights
Rhapsody's portfolio spans advanced materials, semiconductors, photonics, energy, food technology, biomanufacturing, and autonomous-vehicle sensing. Notable companies include:
- GPR (formerly WaveSense) — ground-penetrating radar for autonomous vehicle positioning; inked a $40MM ports-automation contract and was tested at the Port of Rotterdam
- NODAR — stereo-vision "Hammerhead 3D Vision" perception platform for autonomous vehicles
- Holiferm — biosurfactant fermentation technology, with commercial partnerships spanning Sasol, Indorama, and GChem across the US, Europe, and South America
- Manus Bio — biomanufacturing platform for natural ingredients (raised $75M Series B, partnered with the Gates Foundation on malaria treatment R&D)
- ph7 — critical/strategic metals extraction technology
- ChEmpower — launched the industry's first functional pad for abrasive-free semiconductor planarization
- Nuclear Turbines — compact, air-cooled nuclear reactor technology spun out of BAE Systems
Notable exits:
- Apeel Sciences — food-waste-reduction coatings, became a widely covered "unicorn" outcome
- Hazel Technologies — post-harvest produce-freshness technology; new CEO hire and multiple funding rounds tracked in Rhapsody's news feed
- SAFI-Tech — no-heat solder technology, acquired by Indium Corporation (Oct 2023)
- LiquiGlide and VerdaFresh are also listed among the firm's exited investments
Team
Rhapsody is run by a multi-partner team based in Cambridge, MA:
- Carsten Boers — Managing Partner
- Jason Whaley — General Partner
- Jessica Freyer — Partner
- Mike Fuerstman — Partner
- Corrie Kavanaugh — Principal
- Rebecca Wilson — Head of Innovation Ecosystem
- Robert Newman — Associate
- Sarah Hammer, Ph.D. — Associate
Decision Process
With a multi-partner leadership team (Managing Partner, General Partner, and multiple Partners), Rhapsody operates as a partnership rather than a solo-GP or large investment-committee structure.
Founder Preferences
Rhapsody explicitly courts scientific founders — professors, graduate students, and post-docs commercializing deep research — rather than traditional serial software entrepreneurs. The firm markets itself as willing to co-create alongside first-time, technical founders who need help navigating industry partnerships, customer development, and commercialization strategy that generalist VCs typically cannot provide.
Geographic Focus
Primarily United States-based (Cambridge/Boston hub), with an increasingly international portfolio including UK companies (Light Trace Photonics, Biophilica, Nuclear Turbines) and Canadian companies (Cnergreen, Ph7, Latys).
Decision Timeline and Involvement
Not explicitly disclosed on the website; given the firm's "co-creation" positioning and hands-on operational support (industry partnerships, customer introductions, business development), Rhapsody likely takes an active board or advisory role in portfolio companies, consistent with lead seed investors in specialized hard-tech categories.